Benzgalantamine

Last updated

Benzgalantamine
Benzgalantamine.svg
Clinical data
Trade names Zunveyl
Other namesALPHA-1062
AHFS/Drugs.com Zunveyl
License data
Routes of
administration 		By mouth
Drug class Cholinesterase inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C24H25NO4
Molar mass 391.467 g·mol−1
3D model (JSmol)
  • COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
  • InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
  • Key:JKVNJTYHRABHIY-WXVUKLJWSA-N

Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type. [1] It is a cholinesterase inhibitor. [1] Benzgalantamine is a prodrug of galantamine. [1]

Contents

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. [1]

Benzgalantamine was approved for medical use in the United States in July 2024. [1] [2] [3]

Medical uses

Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. [1] [2]

Side effects

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. [1]

Society and culture

Benzgalantamine was approved for medical use in the United States in July 2024. [1] [2]

Names

Benzgalantamine is the international nonproprietary name. [4]

References

  1. 1 2 3 4 5 6 7 8 9 "Zunveyl- benzgalantamine tablet, delayed release". DailyMed. 8 August 2024. Retrieved 15 August 2024.
  2. 1 2 3 fda.gov
  3. ↑ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024– via Business Wire.
  4. ↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl: 10665/363551 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.